Krystexxa resubmission for gout on track for first quarter
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals says that it is on track to re-file the BLA seeking an indication in chronic and treatment-failure gout for Krystexxa (pegloticase) in the first quarter of this year. It received a complete response letter for the drug from the US FDA last July.